LONGBOARD PHARMACEUTICALS IN (LBPH)
US54300N1037 - Common Stock
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates B, LBPH, ZUO on Behalf of Shareholders
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
Longboard Pharmaceuticals Initiates Phase 3 DEEp OCEAN Study Evaluating Bexicaserin in Developmental and Epileptic Encephalopathies (DEEs)
Longboard Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Updates
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RVNC, LBPH, ZUO on Behalf of Shareholders
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates INSI, LBPH, NBR on Behalf of Shareholders
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates LBPH and ARC on Behalf of Shareholders
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates LBPH, MNTX, INSI, ALTM on Behalf of Shareholders
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Longboard Pharmaceuticals, Inc.
/PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by Longboard Pharmaceuticals, Inc. (NASDAQ: LBPH) and its board of...
Top 1% Biotech Longboard Scores A $2.6 Billion Deal And Skyrockets To A Record
Lundbeck will buy Longboard Pharmaceuticals in a deal slated to close in the fourth quarter.
Lundbeck to Buy Longboard Pharmaceuticals in $2.6 Billion Deal
Danish pharmaceutical company H. Lundbeck A/S has agreed to acquire Longboard Pharmaceuticals Inc in a deal with an equity value of $2.6 billion.
Lundbeck to Acquire Longboard Pharmaceuticals in a Strategic Deal, Significantly Enhancing Its Neuroscience Pipeline
Commit To Purchase Longboard Pharmaceuticals At $30, Earn 26.9% Annualized Using Options
Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Noteworthy Friday Option Activity: QCOM, CHRW, LBPH
Longboard Pharmaceuticals Initiates Phase 3 DEEp SEA Study Evaluating Bexicaserin in Dravet Syndrome
Longboard Pharmaceuticals Receives Rare Pediatric Disease Designation and Orphan Drug Designation for Bexicaserin (LP352) in Dravet Syndrome
Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Longboard Pharmaceuticals to Participate in Four Upcoming Investor Conferences in September
Longboard Pharmaceuticals to Present Late-Breaking and Encore Data at the 15th European Epilepsy Congress
Longboard Pharmaceuticals to Host Investor & Analyst Event in New York on September 16, 2024
Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Longboard Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Corporate Updates
Longboard Pharmaceuticals to Report Second Quarter 2024 Financial Results and Host Corporate Update Call on August 1
3 Russell 2000 Growth Stocks That Could Be Worth the Risk
These three small-cap stocks could deliver hefty returns if the central bank cuts rates.